Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Epidemiology, Biomarkers and Prevention

• Publication date

  2002-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 12101108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin-like growth factors in human breast cancer

  2004cited by this paper
• Tamoxifen for Prevention of Breast Cancer

  2003cited by this paper
• Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.

  2002cited by this paper
• Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.

  2001cited by this paper
• Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

  2001cited by this paper
• Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

  2001cited by this paper
• Endogenous estrogens as carcinogens through metabolic activation.

  2000cited by this paper
• Chapter 3: Endogenous Estrogens as Carcinogens Through Metabolic Activation

  2000cited by this paper
• Comparison of serum insulin-like growth factor-1 and growth hormone levels in osteoporotic and non-osteoporotic postmenopausal women

  2000cited by this paper
• Perspectives on cancer chemoprevention research and drug development.

  2000cited by this paper
• Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women.

  2000cited by this paper
• Estrogens as endogenous genotoxic agents--DNA adducts and mutations.

  2000cited by this paper
• Chapter 1: Developmental, Cellular, and Molecular Basis of Human Breast Cancer

  2000cited by this paper
• Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.

  2000cited by this paper
• Bone Turnover Markers and Estradiol Level in Postmenopausal Women

  2000influential reference
• Developmental, cellular, and molecular basis of human breast cancer.

  2000cited by this paper
• Chemoprevention of breast cancer: The Italian experience

  2000cited by this paper
• Effect of body size on breast‐cancer risk among Japanese women

  1999cited by this paper
• Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Body fat distribution and obesity in pre- and postmenopausal breast cancer.

  1999cited by this paper
• A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.

  1999cited by this paper
• Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study.

  1999cited by this paper
• Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

  1999cited by this paper
• Estimation of proliferative activity in normal postmenopausal breast tissue using core biopsy

  1999cited by this paper
• Oestrogen receptor expression in the normal and pre‐cancerous breast

  1999cited by this paper
• BRCA1 and BRCA2: from molecular genetics to clinical medicine.

  1998cited by this paper
• Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy

  1998cited by this paper
• Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.

  1998cited by this paper
• Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.

  1998cited by this paper
• Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.

  1998cited by this paper
• Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.

  1998cited by this paper
• Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen.

  1998cited by this paper
• Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

  1998cited by this paper
• Effects of sex steroids on proliferation in normal mammary tissue.

  1998cited by this paper
• IGF-I physiology and breast cancer.

  1998cited by this paper
• Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: A prospective paired cohort study

  1998cited by this paper
• A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey.

  1997cited by this paper
• Endogenous estrogen and postmenopausal breast cancer: a quantitative review

  1997cited by this paper
• A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey.

  1997cited by this paper
• Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

  1997cited by this paper
• The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels.

  1997cited by this paper
• Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

  1997cited by this paper
• AROMATASE INHIBITORS COME OF AGE

  1997cited by this paper
• Aromatase inhibitors come of age.

  1997cited by this paper
• Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

  1996cited by this paper
• Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk.

  1996cited by this paper
• Serum sex hormone levels after menopause and subsequent breast cancer.

  1996cited by this paper
• Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor.

  1995cited by this paper
• In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

  1995cited by this paper
• Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.

  1994cited by this paper
• Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women.

  1993cited by this paper
• Influence of the antioestrogen tamoxifen on normal breast tissue.

  1991cited by this paper
• Increased cell division as a cause of human cancer.

  1990cited by this paper
• Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: an immunohistochemical study.

  1990cited by this paper
• Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

  1987cited by this paper
• Steroid hormone receptors and carcinoma of the breast.

  1982cited by this paper

• Repurposing of rebamipide as a neuroprotective agent to alleviate letrozole-induced depressive-like behaviors in female rats: Targeting SIRT1/FoxO1/wnt/ β-catenin, and related ferroptosis pathways.

  2025cites this paper
• Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.

  2023cites this paper
• Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis

  2022cites this paper
• Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study

  2020cites this paper
• Preparation of letrozole dispersed pHEMA/AAm-g-LDPE drug release system: In-vitro release kinetics for the treatment of endometriosis.

  2019cites this paper
• Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial

  2018cites this paper
• Genistein and enterolactone in relation to Ki-67 expression and HER2 status in postmenopausal breast cancer patients.

  2017cites this paper
• Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer

  2016cites this paper
• Patterns of change in cognitive function with anastrozole therapy

  2015cites this paper
• Aromatase Inhibitors and Osteoporosis-Risk, Prevention and Treatment Review

  2015cites this paper
• Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review

  2015cites this paper
• Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk

  2015cites this paper
• Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures

  2015cites this paper
• DRAMATIC MONOLOGUES: THE GRAMMATICALIZATION OF SPEAKING ROLES IN COURTROOM OPENING STATEMENTS

  2014cites this paper
• Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

  2014cites this paper
• The Levels of Ki-67 Positive are Positively Associated with Lymph Node Metastasis in Invasive Ductal Breast Cancer

  2014cites this paper
• A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer

  2013cites this paper
• Effects of methyltestosterone, letrozole, triphenyltin and fenarimol on histology of reproductive organs of the copepod Acartia tonsa.

  2013cites this paper
• Correlation between Ki67 and Breast Cancer Prognosis

  2013cites this paper
• Cardiovascular Health and Aromatase Inhibitors

  2012cites this paper
• Valdecoxib

  2012cites this paper
• Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study

  2012influential citation
• Effect of anastrozole on bone mineral density and lipid profiles when used to prevent breast cancer in high risk postmenopausal women

  2012cites this paper
• Cathepsin D: A Novel Target for Apoptotic Induction, as a Future Anti-Cancer Therapy: a Review

  2012cites this paper
• Letrozole

  2012cites this paper
• A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

  2012cites this paper
• celecoxib in patients with primary breast cancer

  2011cites this paper
• Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.

  2011cites this paper
• Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome

  2011cites this paper
• A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

  2011cites this paper
• Modulation of Intracrine Estrogen in Menopausal Women: Implications for Women’s Reproductive Health and Breast Cancer Risk

  2011cites this paper
• Short-Term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer

  2011cites this paper
• An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer

  2011cites this paper
• Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancer.

  2010cites this paper
• Bisphosphonates, Bone Health and the Clinical Biology of Bone Metastases from Breast Cancer

  2010cites this paper
• Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer

  2010cites this paper
• 2008 Santa Fe Bone Symposium: update on osteoporosis.

  2009cites this paper
• Aromatase inhibitors: potential reproductive implications.

  2009cites this paper
• Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma.

  2009cites this paper
• Menopausal estrogen deprivation activates steroid sensitive stem cells (3SC) and local estrogen biosynthesis: A model for breast cancer development

  2009cites this paper
• Effects of letrozole on bone biomarkers and femur fracture in female rats

  2009cites this paper
• Letrozole

  2009cites this paper
• Mecanisme a nanocanal et methodes associees

  2009cites this paper
• Surrogate response biomarkers in prevention research: do they point the way or lead us astray?

  2009cites this paper
• The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer

  2008cites this paper
• Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

  2008cites this paper
• Description and Pre-clinical Validation of Dynamic Molecular Determinants of Sensitivity to Aromatase Inhibitors in Breast Cancer

  2008cites this paper
• Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition.

  2008cites this paper
• Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.

  2008cites this paper
• Criteria for the evaluation of large cohort studies: an application to the nurses' health study.

  2008cites this paper
• Neoadjuvant endocrine therapy for breast cancer: past, present and future

  2008cites this paper
• Possible additional therapeutic uses of aromatase inhibitors

  2008cites this paper
• Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy

  2008influential citation
• Impact of Estrogen Deprivation on Gene Expression Profiles of Normal Postmenopausal Breast Tissue In vivo

  2008influential citation
• Long-term side effects of adjuvant breast cancer treatment

  2008cites this paper
• Indications and limitations of third-generation aromatase inhibitors

  2008cites this paper
• The influence of endocrine treatments for breast cancer on health-related quality of life.

  2008cites this paper
• Long-term side effects of adjuvant breast cancer treatment

  2008cites this paper
• Response and resistance to the endocrine prevention of breast cancer.

  2008cites this paper
• Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer

  2008cites this paper
• Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer

  2008cites this paper
• Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials

  2007cites this paper
• Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women

  2007cites this paper
• Use of biomarkers for breast cancer risk assessment and prevention.

  2007cites this paper
• Reducing the risk of early recurrence in hormone-responsive breast cancer.

  2007cites this paper
• Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.

  2007cites this paper
• Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective

  2007cites this paper
• Summary of aromatase inhibitor trials: the past and future.

  2007cites this paper
• Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy.

  2007cites this paper
• Aromatase inhibitors and bone.

  2007cites this paper
• Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer.

  2007cites this paper
• Reduction in proliferation with six months of letrozole in women on hormone replacement therapy

  2007influential citation
• Effects of aromatase inhibitors letrozole and anastrazole on bone metabolism and steroid hormone levels in intact female rats

  2007cites this paper
• Effects of adjuvant aromatase inhibitor therapy on lipid profiles

  2006cites this paper
• Endocrine Therapy of Breast Cancer

  2006cites this paper
• Aromatase inhibitors and bone health

  2006influential citation
• Molecular Modelling Analysis of the Metabolism of Letrozole

  2006cites this paper
• Modification of oestrogen signalling during the acquisition of hormone resistance in breast cancer cells

  2006cites this paper
• The balance between risks and benefits: Long-term use of aromatase inhibitors

  2006cites this paper
• Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.

  2006cites this paper
• Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects

  2006cites this paper
• The ne w e ngl and j our na l of medicine

  2006cites this paper
• Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)

  2006cites this paper
• Effects of third-generation aromatase inhibitors on bone.

  2006cites this paper
• Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.

  2006cites this paper
• Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer

  2006cites this paper
• The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98.

  2006cites this paper
• Appraising adjuvant aromatase inhibitor therapy.

  2006cites this paper
• The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.

  2006cites this paper
• Aromatase inhibitors and bone health in women with breast cancer.

  2006cites this paper
• Avian Contraceptive Tools: One Size Does Not Fit All

  2006cites this paper
• Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use.

  2006cites this paper
• Letrozole in the treatment of breast cancer

  2005cites this paper
• The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

  2005cites this paper
• Aromatase inhibitors in the treatment of early and advanced breast cancer

  2005cites this paper
• Long-term effects of aromatase inhibitors on bone.

  2005cites this paper
• Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

  2005cites this paper
• Optical transillumination spectroscopy to quantify parenchymal tissue density: an indicator for breast cancer risk.

  2005cites this paper
• The biology of steroid hormones and endocrine treatment of breast cancer.

  2005cites this paper
• Advances in adjuvant hormonal therapy for postmenopausal women.

  2005cites this paper